Is it safe?
Can NVO take a bad year?
Novo Nordisk A/S carries $116.0B of net debt at 0.78× EBITDA: a load its earnings can carry.
$116.0B
Net debt · as at FY2025 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 0.78×
Net debt / EBITDA · 0.61× a year ago · the load is going up
- Interest cover
- 30.3×
Interest cover · operating profit covers the interest bill several times over
- Annualised volatility
- 49%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Total debtFY2025
- $143.0B
- Cash and short-term investments
- $27.0B
- Net debt
- $116.0B
- EBITDA, trailing twelve months
- $149.6B
- Operating profit, trailing twelve months
- $127.7B
- Debt / equity
- 0.74×
- Total debt / EBITDA
- 0.95×
- Annualised volatilitytwo years of daily moves
- 49%
- Worst drawdown on file
- −75%
- Below its 52-week high
- −24%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers - General
Ranks #4 of 16 by Smart Score